M-63 Infant Probiotic Composition for Early Gut Colonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The intestinal microbiota in newborns, infants, and small children is unstable and prone to disturbances, leading to a high risk of infection and other health issues, and existing probiotics like Bifidobacterium longum subsp. infantis M-63 have not fully addressed the need for promoting early colonization and maintaining a healthy intestinal environment.
Innovation Solution
A composition containing Bifidobacterium longum subsp. infantis M-63, in the form of bacterial cells, cultures, or treated products, is administered to healthy full-term newborns, infants, or small children to promote early colonization, maturation of intestinal function, suppress milk regurgitation, and regulate immune function, preferably at a dosage of 1.0×10^8 to 5.0×10^9 cfu/kg body weight/day, often in combination with breast feeding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Bifidobacterium longum subsp. infantis M-63 is administered to promote colonization, then the intestinal environment is improved, but the stability of the intestinal microbiota remains insufficient in newborns and infants
Solution Approach 1:
The patent changes the key parameter from simply administering any Bifidobacterium to administering a specifically selected strain (B. longum subsp. infantis M-63) with optimized characteristics. This strain selection represents a parameter change that ensures both colonization promotion and microbiota stability, resolving the contradiction between improving the intestinal environment and maintaining microbiota stability.
2Object-affected harmful factors
If probiotics are administered to establish Bifidobacterium-dominant microbiota, then intestinal health is improved, but the risk of infection and disturbances remains high in the neonatal period
Solution Approach 1:
The patent applies preliminary action by administering the selected Bifidobacterium strain during the neonatal period and early infancy when the intestinal microbiota is still developing. This early intervention establishes a stable, Bifidobacterium-dominant microbiota before harmful disturbances can occur, thereby reducing infection risk while ensuring microbiota reliability.
Solution Approach 2:
The patent uses a specific, well-characterized strain (M-63) that can be reliably produced and administered as a standardized probiotic product. This approach replaces the need for complex, unstable natural microbiota transfers with a consistent, controllable probiotic intervention that provides reliable protection against infections.
3Productivity
If existing probiotics are used, then some intestinal benefits are achieved, but early colonization promotion and intestinal maturation are not fully addressed
Solution Approach 1:
The patent applies local quality by selecting a probiotic strain specifically adapted to infant intestinal conditions. The B. longum subsp. infantis M-63 strain possesses local characteristics (infant-specific adaptation) that enable it to effectively colonize and promote intestinal maturation in the unique environment of the infant gut, achieving both high productivity in maturation and reliability in colonization.
Data Source
Figure 1
Figure 2(a)~2(c)
Figure 3(a)~3(c)
AI summary
An object is to provide a new function of Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623). One kind or two or more kinds selected from bacterial cells of Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623), a culture of the bacterium and a treated product of the bacterium is added to a composition taken by a healthy full-term newborn, infant or small child as an active ingredient. The composition is subjected to use for promoting colonization of a strain of Bifidobacterium in an intestinal microbiota, use for promoting maturation of an intestinal function, use for suppressing milk regurgitation or use for regulating immune function.